| Active substance | Tolebrutinib |
| Holder | Sanofi Belgium |
| Status | Running |
| Indication | Tolebrutinib is indicated for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS) in adults. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 10/04/2026 |